Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EOS100850 |
Synonyms | |
Therapy Description |
EOS100850 is an antagonist that selectively targets the A2A receptor and inhibits downstream signaling, which potentially induces an inflammatory response against tumor cells (Cancer Res 2019;79(13 Suppl):Abstract nr 4147). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EOS100850 | EOS-100850|EOS 100850|Inupadenant | Adenosine Targeting 23 | EOS100850 is an antagonist that selectively targets the A2A receptor and inhibits downstream signaling, which potentially induces an inflammatory response against tumor cells (Cancer Res 2019;79(13 Suppl):Abstract nr 4147). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03873883 | Phase I | EOS100850 + Pembrolizumab EOS100850 | First-in-Human Study of EOS100850 in Patients With Cancer | Completed | USA | GBR | FRA | ESP | BEL | 1 |
NCT05117177 | Phase I | EOS100850 | New Formulation Study of Inupadenant (EOS100850) in Patients With Cancer | Completed | GBR | BEL | 0 |